Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dalpiciclib + fulvestrant + compound gossypol acetate
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Dalpiciclib + fulvestrant + compound gossypol acetate is an investigational triple-drug combination therapy currently under clinical evaluation for the treatment of advanced breast cancer. The regimen consists of **dalpiciclib** (SHR6390), a selective small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); **fulvestrant**, a selective estrogen receptor degrader (SERD); and **compound gossypol acetate**, a natural polyphenolic compound that acts as a BH3 mimetic and inhibitor of anti-apoptotic Bcl-2 family proteins. This combination is designed to simultaneously target the CDK4/6-Rb cell cycle pathway, estrogen receptor signaling, and apoptotic escape mechanisms. It is primarily being studied in patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have previously progressed on or failed treatment with other CDK4/6 inhibitors, aiming to overcome endocrine and cell-cycle-related resistance.
- Brand names
- Darcilie
- Other names
- dalpiciclib + fluvestrant + compound gossypol acetatedalpiciclib + fulvestrant + gossypol acetate
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)ESR1 (ERα)ESR2 (ERβ)MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on dalpiciclib + fulvestrant + compound gossypol acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dalpiciclib + fulvestrant + compound gossypol acetate.